Hikma Pharmaceuticals Projects Strong Growth and Rebrands Generics Business

The latest update is out from Hikma Pharmaceuticals ( (GB:HIK) ).

Hikma Pharmaceuticals announced strong medium-term growth guidance for its Group, projecting a 6% to 8% CAGR in revenue and a 7% to 9% CAGR in core operating profit from 2024 to 2027. The company aims to achieve $5 billion in Group revenue by 2030 and is rebranding its Generics business to Hikma Rx, emphasizing its focus on complex prescription medicines. This strategic move and growth projection highlight Hikma’s commitment to sustainable growth and its significant role in the US generic medicines market.

The most recent analyst rating on (GB:HIK) stock is a Buy with a £2500.00 price target. To see the full list of analyst forecasts on Hikma Pharmaceuticals stock, see the GB:HIK Stock Forecast page.

Spark’s Take on GB:HIK Stock

According to Spark, TipRanks’ AI Analyst, GB:HIK is a Outperform.

Hikma Pharmaceuticals shows strong financial performance with consistent revenue and profit growth, supported by positive corporate events such as managerial share acquisitions and a credit rating upgrade. While the valuation remains attractive, technical indicators suggest caution due to recent bearish momentum. Overall, the stock presents a solid long-term investment potential, tempered by some immediate market weaknesses.

To see Spark’s full report on GB:HIK stock, click here.

More about Hikma Pharmaceuticals

Hikma Pharmaceuticals is a multinational pharmaceutical group that is one of the largest suppliers of generic medicines in the US. The company operates in the pharmaceutical industry, focusing on the production of oral, respiratory, and other generic and specialty products, with a strong presence in the US market.

Average Trading Volume: 550,906

Technical Sentiment Signal: Buy

Current Market Cap: £4.29B

See more data about HIK stock on TipRanks’ Stock Analysis page.